EliteImmune focuses on creating antibody-based drugs for targeted therapy and prophylaxis of infectious diseases. Powered by our proprietary CellProbe™ and CellSeq™ platforms, we pinpoint naturally occurring leads by high-resolution and high-throughput screening of B cell repertoires from elite donors. We have a robust pipeline of rare antibodies with superior selectivity, affinity, and therapeutic efficacy to combat deadly infectious diseases.

Eliteimmune is poised to enter the immuno-oncology and aging space with novel antibodies targeting neoantigens. We seek to establish partnerships with global pharmaceutical and biotech companies for future licensing and co-development.